Integrated screening identifies GPR31 as a key driver and druggable target for metabolic dysfunction–associated steatohepatitis
Journal of Clinical Investigation · 2025
DOI: 10.1172/jci173193 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Xiao-Jing Zhang und 29 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Gannan Innovation and Translational Medicine Research Institut…. Hauptthemen laut MEDLINE: Receptors, G-Protein-Coupled, Fatty Liver, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Hubei Provincial Natural Science Foundation, the Jiangxi Provincial Natural Science Foundation, the Jiangxi Province Thousand Talents Project.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Gannan Innovation and Translational Medicine Research Institute, School of Pharmacy, First Affiliated Hospital, Gannan Medical Unive…
- Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China.
- State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, China.
- School of Basic Medical Sciences, Wuhan University, Wuhan, China.
- Department of Cardiology and.
- Department of Radiology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Förderung
- the Hubei Provincial Natural Science Foundation
- the Jiangxi Provincial Natural Science Foundation
- the Jiangxi Province Thousand Talents Project
- the Basic Medicine-Clinical Medicine Transformation Collaborative Fund of Zhongnan Hospital of Wuhan University
- Henan Charity Federation Hepatobiliary Fund
- Key R&D Programmes of Science and Technology Department of Jiangxi Province
- Key R&D Programmes of Ganzhou
- the Huanggang Joint Fund for Innovation and Development
Zitieren
APA
Zhang, X. J., Fu, J., Cheng, X., Shen, H., Yang, H., Wang, K., Li, W., Tian, H., Tian, T., Zhou, J., Tian, S., Wang, Z., Wan, J., Bai, L., Duan, H., Zhang, X., Tian, R., Xu, H., Liao, R., …, & Li, H. (2025). Integrated screening identifies GPR31 as a key driver and druggable target for metabolic dysfunction–associated steatohepatitis. Journal of Clinical Investigation. https://doi.org/10.1172/jci173193
Vancouver
Zhang XJ, Fu J, Cheng X, Shen H, Yang H, Wang K, et al. Integrated screening identifies GPR31 as a key driver and druggable target for metabolic dysfunction–associated steatohepatitis. Journal of Clinical Investigation. 2025. doi:10.1172/jci173193
BibTeX
@article{Zhang2025,
author = {Zhang, Xiao-Jing and Fu, Jiajun and Cheng, Xu and Shen, Hong and Yang, Hailong and Wang, Kun and Li, Wei and Tian, Han and Tian, Tian and Zhou, Junjie and Tian, Song and Wang, Zhouxiang and Wan, Juan and Bai, Lan and Duan, Hongfei and Zhang, Xin and Tian, Ruifeng and Xu, Haibo and Liao, Rufang and Zou, Toujun and Shi, Jing and Qu, Weiyi and Fang, Liang and Cai, Jingjing and Zhang, Peng and She, Zhi-Gang and Jiang, Jingwei and Hu, Yufeng and Wang, Yibin and Li, Hongliang},
title = {Integrated screening identifies GPR31 as a key driver and druggable target for metabolic dysfunction–associated steatohepatitis},
journal = {Journal of Clinical Investigation},
year = {2025},
doi = {10.1172/jci173193}
}
EUVIMED